ANGIODYNAMICS INC - Quarter Report: 2010 November (Form 10-Q)

ANGIODYNAMICS INC - Quarter Report: 2010 November (Form 10-Q)

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2010

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-50761

AngioDynamics, Inc.

(Exact name of registrant as specified in its charter)


Delaware		11-3146460
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

14 Plaza Drive Latham, New York		12110
(Address of principal executive offices)		(Zip Code)

(518) 795-1400

Registrant’s telephone number, including area code

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date.


Class		Outstanding as of January 3, 2011
Common Stock, par value $.01		24,943,110 shares

AngioDynamics, Inc. and Subsidiaries

INDEX


		Page
Part I: Financial Information
Item 1.	Financial Statements

	Consolidated Statements of Income – three and six months ended November 30, 2010 and November 30, 2009 (unaudited)	3

	Consolidated Balance Sheets – November 30, 2010 and May 31, 2010 (unaudited)	4

	Consolidated Statements of Cash Flows – six months ended November 30, 2010 and November 30, 2009 (unaudited)	5

	Consolidated Statement of Stockholders’ Equity and Comprehensive Income – six months ended November 30, 2010 (unaudited)	6

	Notes to Consolidated Financial Statements (unaudited)	7 – 18

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19 – 25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	25

Part II: Other Information

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	(Removed and Reserved)	26

Item 5.	Other Information	26

Item 6.	Exhibits	26

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in thousands, except per share data)


	Three Months Ended						Six Months Ended
	Nov 30, 2010			Nov 30, 2009			Nov 30, 2010			Nov 30, 2009
Net sales	$	53,372		$	53,459		$	104,879		$	103,551
Cost of sales		21,836			21,852			43,323			41,812

Gross profit		31,536			31,607			61,556			61,739

Operating expenses
Research and development		5,259			4,763			10,501			9,612
Sales and marketing		13,793			15,042			28,237			30,401
General and administrative		4,945			4,031			9,532			8,108
Amortization of intangibles		2,142			2,451			4,408			4,723

Total operating expenses		26,139			26,287			52,678			52,844

Operating income		5,397			5,320			8,878			8,895

Other income (expenses)
Interest income		161			162			328			350
Interest expense		(116	)		(237	)		(240	)		(408	)
Other expense		(307	)		(215	)		(878	)		(397	)

Total other income (expenses)		(262	)		(290	)		(790	)		(455	)

Income before income tax provision		5,135			5,030			8,088			8,440
Income tax provision		1,856			1,901			2,921			3,200

Net income	$	3,279		$	3,129		$	5,167		$	5,240

Earnings per common share
Basic	$	0.13		$	0.13		$	0.21		$	0.21

Diluted	$	0.13		$	0.13		$	0.21		$	0.21


Basic weighted average shares outstanding		24,845			24,518			24,799			24,472
Diluted weighted average shares outstanding		25,094			24,729			25,067			24,662

The accompanying notes are an integral part of these interim consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except share data)


	Nov 30, 2010			May 31, 2010
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	27,132		$	58,763
Marketable securities, at fair value		83,471			41,311

Total cash, cash equivalents and marketable securities		110,603			100,074
Accounts receivable, net of allowances of $477 and $558, respectively		25,762			29,838
Inventories		32,731			29,216
Deferred income taxes		2,997			5,281
Prepaid expenses and other		5,353			6,951

Total current assets		177,446			171,360
PROPERTY, PLANT AND EQUIPMENT-AT COST, less accumulated depreciation		24,102			24,193
OTHER ASSETS		2,766			2,557
INTANGIBLE ASSETS, less accumulated amortization		53,948			58,352
GOODWILL		161,964			161,974
DEFERRED INCOME TAXES, long term		2,598			2,527
PREPAID ROYALTIES		3,159			2,962

TOTAL ASSETS	$	425,983		$	423,925


LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	8,056		$	12,044
Accrued liabilities		11,795			13,722
Current portion of long-term debt		270			260

Total current liabilities		20,121			26,026
LONG-TERM DEBT, net of current portion		6,410			6,550

Total liabilities		26,531			32,576

COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued and outstanding 24,851,862 and 24,747,145 shares at November 30, 2010 and May 31, 2010, respectively		248			247
Additional paid-in capital		368,287			365,344
Retained earnings		32,319			27,152
Accumulated other comprehensive loss		(1,402	)		(1,394	)

Total stockholders’ equity		399,452			391,349

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	425,983		$	423,925

The accompanying notes are an integral part of these interim consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)


	Six Months Ended
	Nov 30, 2010			Nov 30, 2009
Cash flows from operating activities:
Net income	$	5,167		$	5,240
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		5,984			6,219
Tax effect on exercise of stock options and issuance of performance shares		(29	)		31
Deferred income taxes		2,285			3,126
Change in allowance for excess and obsolete inventory		(38	)		(462	)
Stock based compensation		2,254			2,413
Imputed interest		—			153
Change in accounts receivable allowances		(81	)		(32	)
Other		153			17
Changes in operating assets and liabilities:
Accounts receivable		4,157			1,816
Inventories		(3,477	)		(2,767	)
Prepaid expenses and other		1,195			931
Accounts payable and accrued liabilities		(5,944	)		(4,304	)

Net cash provided by operating activities		11,626			12,381

Cash flows from investing activities:
Additions to property, plant and equipment		(1,489	)		(1,951	)
Acquisition of intangible assets and business		—			(5,350	)
Purchases of marketable securities		(128,274	)		(17,823	)
Proceeds from sale or maturity of marketable securities		85,880			20,254

Net cash used in investing activities		(43,883	)		(4,870	)

Cash flows from financing activities:
Repayment of long-term debt		(130	)		(145	)
Proceeds from exercise of stock options and employee stock purchase plan		718			971

Net cash provided by financing activities		588			826

Effect of exchange rate changes on cash and cash equivalents		38			10

(Decrease) increase in cash and cash equivalents		(31,631	)		8,347

Cash and cash equivalents at beginning of period		58,763			27,909

Cash and cash equivalents at end of period	$	27,132		$	36,256

The accompanying notes are an integral part of these interim consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY AND

COMPREHENSIVE INCOME

Six Months Ended November 30, 2010

(unaudited)

(in thousands, except share data)


	Common Stock				Additional paid in capital			Retained earnings		Accumulated other comprehensive loss			Total			Comprehensive income
	Shares		Amount		Additional paid in capital			Retained earnings		Accumulated other comprehensive loss			Total			Comprehensive income
Balance at May 31, 2010		24,747,145	$	247	$	365,344		$	27,152	$	(1,394	)	$	391,349
Net income									5,167					5,167		$	5,167
Exercise of stock options		27,875		—		117			—		—			117			—
Purchase of common stock under Employee Stock Purchase Plan		46,496		1		601			—		—			602			—
Issuance/Cancellation of performance shares		30,346		—		—			—		—			—			—
Tax effect of exercise of stock options		—		—		(29	)		—		—			(29	)		—
Stock based compensation		—		—		2,254			—		—			2,254			—
Unrealized loss on marketable securities, net of tax of $66		—		—		—			—		(112	)		(112	)		(112	)
Unrealized loss on interest rate swap, net of tax of $12		—		—		—			—		(21	)		(21	)		(21	)
Foreign currency translation		—		—		—			—		125			125			125

Comprehensive income																$	5,159

Balance at November 30, 2010		24,851,862	$	248	$	368,287		$	32,319	$	(1,402	)	$	399,452

The accompanying notes are an integral part of these interim consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

November 30, 2010 and November 30, 2009

(unaudited)

NOTE A – CONSOLIDATED FINANCIAL STATEMENTS

The consolidated balance sheet as of November 30, 2010, the consolidated statement of stockholders’ equity and comprehensive income for the six months ended November 30, 2010, the consolidated statement of cash flows for the six months ended November 30, 2010 and November 30, 2009 and the consolidated statements of income for the three and six months ended November 30, 2010 and November 30, 2009 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2010 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normally recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2010 (and for all periods presented) have been made.

Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 31, 2010, filed by us on August 6, 2010. The results of operations in the fiscal periods ended November 30, 2010 and November 30, 2009 are not necessarily indicative of the operating results for the respective full fiscal years.

The unaudited interim consolidated financial statements for the three and six months ended November 30, 2010 and 2009 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, RITA Medical Systems, LLC, and AngioDynamics UK Limited (collectively, the “Company”). All intercompany balances and transactions have been eliminated.

Previously we organized our business into three reportable segments: Peripheral Vascular, Access and Oncology. Effective June 1, 2010, we combined our Peripheral Vascular and Access reportable segments into a single reportable segment that was named the Vascular division and placed under the leadership of a general manager. At the same time we combined what had been separate Peripheral Vascular and Access sales groups into the Vascular sales group under the leadership of a vice president of sales reporting to the general manager. The Vascular segment is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology segment continues to be responsible for RF Ablation, embolization, Habib and NanoKnife product lines and has dedicated research and development and sales and marketing personnel assigned to it.

The measure of financial performance and profitability that management uses to evaluate the performance of our business segments are sales, gross profit, and operating income. Effective June 1, 2010, we reorganized our internal management reporting to reflect the two reportable segments described above. Segment information reported for the prior year has been recast to conform to the current year presentation.

NOTE B – ACQUISITIONS

FlowMedica, Inc.

On January 12, 2009, we completed the acquisition of certain assets of FlowMedica, Inc. for approximately $1.75 million in cash and a contingent payment based on fiscal 2011 sales of FlowMedica products. With this acquisition, we purchased the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy. Intangible assets acquired totaled approximately $1.3 million which have been identified as product technologies (10-year weighted average useful life). Inventory acquired totaled approximately $400,000. The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective January 12, 2009. The pro-forma effects of the acquisition were not material to our income statement and balance sheet. Ten employees of FlowMedica, Inc. became employees upon completion of the acquisition.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE C – INVENTORIES

Inventories consist of the following:


	Nov 30, 2010			May 31, 2010
	(in thousands)
Raw materials	$	11,673		$	11,817
Work in process		3,509			3,657
Finished goods		19,712			15,943

Gross Inventories		34,894			31,417
Less: Reserves		(2,163	)		(2,201	)

Inventories	$	32,731		$	29,216

NOTE D – GOODWILL AND INTANGIBLE ASSETS

Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. None of our intangible assets have an indefinite life. Intangible assets with determinable useful lives are amortized over their useful lives on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.

For goodwill, the evaluation requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows. We test goodwill for impairment during the third quarter of every fiscal year, or more frequently if impairment indicators arise. Events that could, in the future, result in impairment include, but are not limited to, sharply declining sales for a significant product or in a significant geographic region.

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Previously we organized our business into three reportable segments: Peripheral Vascular, Access and Oncology. Effective June 1, 2010, we combined our Peripheral Vascular and Access reportable segments into a single reportable segment that was named the Vascular division and placed under the leadership of a general manager. At the same time we combined what had been separate Peripheral Vascular and Access sales groups into the Vascular sales group under the leadership of a vice president of sales reporting to the general manager. The Vascular segment is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology segment continues to be responsible for RF Ablation, embolization, Habib and NanoKnife product lines and has dedicated research and development and sales and marketing personnel assigned to it.

We completed our annual evaluation of goodwill by reporting unit as of December 31, 2009, using the three reportable segments in place at that time. Our assessment of goodwill impairment indicated that the fair value of each of our reporting units exceeded its carrying value and therefore goodwill in each of the reporting units was not impaired. The reorganization into two reportable segments would not have changed the outcome of the assessment since we effectively combined two segments which independently were not impaired. The fair value of Peripheral Vascular, Access and Oncology exceeded its carrying value by 26%, 6% and 16%, respectively. The sum of the fair values of the reporting units was reconciled to our current market capitalization (based upon our stock price) plus an estimated control premium of approximately 8% as of December 31, 2009.

To determine fair value, we utilized two market-based approaches and an income approach. Under the market-based approaches, we utilized information regarding our own as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, we determined fair value based on estimated future cash flows of each reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We determined the discounted cash flow as the best indicator to determine fair value.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE D – GOODWILL AND INTANGIBLE ASSETS – (cont’d)

Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. Solely for purposes of establishing inputs for the fair value calculations, we assumed that the current economic conditions would continue through fiscal year 2011, followed by a recovery thereafter. In addition, we applied gross margin assumptions consistent with our historical trends at various revenue levels and used an EBITDA exit multiple of 6.0, 6.0 and 7.0 to calculate the terminal value of the Peripheral Vascular, Access and Oncology reporting units, respectively, compared to an EBITDA exit multiple of 6.5, 7.0 and 8.0, respectively, used in the prior year. In addition, we used a discount rate of 21%, 15% and 18% to calculate the fair value of our Peripheral Vascular, Access and Oncology reporting units, respectively. These discount rates vary from the rates of 19%, 16% and 19%, respectively, used in the prior year.

Since early November 2008, our stock market capitalization has generally been lower than our shareholders’ equity or book value. However, our reporting units have continued to generate significant cash flow from their operations, and we expect that they will continue to do so in fiscal 2011 and beyond. Furthermore, given the relatively small difference between our stock price and our book value per share, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our trading prices and our book value.

Goodwill by segment is as follows:


	Nov 30, 2010
Vascular	$	107,972
Oncology		53,992

	$	161,964


	May 31, 2010
Vascular	$	107,982
Oncology		53,992

	$	161,974

Even though we determined that there was no goodwill impairment as of December 31, 2009, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that a reporting unit or a significant portion of a reporting unit will be sold or disposed of, would require an interim assessment for some or all of the reporting units prior to the next required annual assessment as of December 31, 2010. It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material.

During the six months ended November 30, 2010, options assumed in connection with the acquisition of RITA Medical Systems, Inc. were exercised causing an adjustment to the purchase price allocation as noted below. The exercise will result in a tax benefit when the annual tax return is filed.

Changes in the carrying amount of goodwill for the six months ended November 30, 2010 are as follows (in thousands):


Balance, May 31, 2010	$	161,974
Adjustments to purchase price allocation		(10	)

Balance, November 30, 2010	$	161,964

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE D – GOODWILL AND INTANGIBLE ASSETS – (cont’d)

Intangible assets are amortized over their estimated useful lives. The balances of intangible assets are as follows:


	November 30, 2010
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	48,648	$	(14,366	)	$	34,282		13.5
Customer relationships		31,125		(15,289	)		15,836		7.5
Licenses		6,040		(2,655	)		3,385		9.2
Distributor relationships		900		(900	)		—		3.0
Trademarks		675		(230	)		445		9.2

	$	87,388	$	(33,440	)	$	53,948


	May 31, 2010
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	48,648	$	(12,341	)	$	36,307		13.5
Customer relationships		31,125		(13,216	)		17,909		7.5
Licenses		6,040		(2,379	)		3,661		9.2
Distributor relationships		900		(900	)		—		3.0
Trademarks		675		(200	)		475		9.2

	$	87,388	$	(29,036	)	$	58,352

NOTE E – ACCRUED LIABILITIES

Accrued liabilities consist of the following:


	Nov 30, 2010		May 31, 2010
	(in thousands)
Payroll and related expenses	$	6,469	$	8,444
Royalties		1,394		1,508
Sales and franchise taxes		1,162		1,017
Fair value of interest rate swap		1,139		995
Other		1,631		1,758

Total	$	11,795	$	13,722

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE F – INCOME TAXES

Our effective income tax rate for the three month periods ending November 30, 2010 and November 30, 2009 was 36% and 38%, respectively. Our effective income tax rate for the six month periods ending November 30, 2010 and November 30, 2009 was 36% and 38%, respectively. Both the three and six months periods ending November 30, 2010 reflect an increased benefit from the Domestic Production Activities Deduction which was partially offset by the December 31, 2009 expiration of the R&D tax credit.

NOTE G – EARNINGS PER COMMON SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share further includes the dilutive effect of potential common stock consisting of stock options, warrants, and restricted stock units, provided that the inclusion of such securities is not antidilutive.

The following table sets forth the reconciliation of the weighted-average number of common shares:


	Three Months Ended				Six Months Ended
	Nov 30, 2010		Nov 30, 2009		Nov 30, 2010		Nov 30, 2009
Basic		24,845,305		24,518,420		24,799,247		24,472,403
Effect of dilutive securities		248,818		210,613		267,329		189,931

Diluted		25,094,123		24,729,033		25,066,576		24,662,334

Excluded from the calculation of diluted earnings per common share are options and restricted stock awards issued to employees and non-employees to purchase 2,463,014 and 2,196,891 shares of common stock for the three and six months ended November 30, 2010 and options and restricted stock awards issued to employees and non-employees to purchase 2,431,567 and 2,387,409 shares of common stock for the three and six months ended November 30, 2009, as their inclusion would be antidilutive. The exercise prices of these options and restricted stock awards were between $0 and $53.92 at November 30, 2010.

NOTE H – SEGMENT AND GEOGRAPHIC INFORMATION

Previously we organized our business into three reportable segments: Peripheral Vascular, Access and Oncology. Effective June 1, 2010, we combined our Peripheral Vascular and Access reportable segments into a single reportable segment that was named the Vascular division and placed under the leadership of a general manager. At the same time we combined what had been separate Peripheral Vascular and Access sales groups into the Vascular sales group under the leadership of a vice president of sales reporting to the general manager. The Vascular segment is responsible for products targeting the venous intervention, venous access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology segment continues to be responsible for RF Ablation, embolization, Habib and NanoKnife product lines and has dedicated research and development and sales and marketing personnel assigned to it.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE H – SEGMENT AND GEOGRAPHIC INFORMATION – (cont’d)

Selected information by reportable segment is presented in the following tables (in thousands):


	Three Months Ended					As a Percentage of Net Sales Three Months Ended
	Nov 30, 2010		Nov 30, 2009			Nov 30, 2010			Nov 30, 2009
Net sales
Vascular	$	37,520	$	39,844
Oncology		15,852		13,615

Total	$	53,372	$	53,459

Gross profit
Vascular	$	21,111	$	22,811			56.3	%		57.3	%
Oncology		10,425		8,796			65.8	%		64.6	%

Total	$	31,536	$	31,607			59.1	%		59.1	%

Operating income (loss)
Vascular	$	4,768	$	5,202			12.7	%		13.1	%
Oncology		629		118			4.0	%		0.9	%

Total	$	5,397	$	5,320			10.1	%		10.0	%


	Six Months Ended					As a Percentage of Net Sales Six Months Ended
	Nov 30, 2010		Nov 30, 2009			Nov 30, 2010			Nov 30, 2009
Net sales
Vascular	$	73,434	$	77,134
Oncology		31,445		26,417

Total	$	104,879	$	103,551

Gross profit
Vascular	$	41,256	$	44,810			56.2	%		58.1	%
Oncology		20,300		16,929			64.6	%		64.1	%

Total	$	61,556	$	61,739			58.7	%		59.6	%

Operating income (loss)
Vascular	$	7,845	$	9,277			10.7	%		12.0	%
Oncology		1,033		(382	)		3.3	%		(1.4	%)

Total	$	8,878	$	8,895			8.5	%		8.6	%

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE H – SEGMENT AND GEOGRAPHIC INFORMATION – (cont’d)

In accordance with accounting policies on disclosure of segment reporting, the internal organization that is used by management for making operating decisions and assessing performance is used as the source of our reportable segments. The accounting policies of the segments are the same as those described in Accounting Policies, Note 1, of our Annual Report on Form 10-K for the fiscal year ended May 31, 2010, filed by us on August 6, 2010. The measure of financial performance and profitability that management uses to evaluate the performance of our business segments are sales, gross profit, and operating income. Segment information reported for the prior year has been recast to conform to the current year presentation.

Total sales for geographic areas are summarized below (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2010		Nov 30, 2009		Nov 30, 2010		Nov 30, 2009
Net Sales by Geography
United States	$	46,703	$	47,488	$	92,176	$	92,401
International		6,669		5,971		12,703		11,150

Total	$	53,372	$	53,459	$	104,879	$	103,551

NOTE I – FAIR VALUE

Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, short-term and long-term debt and two interest rate swap agreements. The carrying amount of these instruments approximates fair value due to the immediate or short-term maturities and variable interest rates associated with these instruments. Marketable securities are carried at their fair value as determined by quoted market prices.

Effective June 1, 2008, we adopted an accounting policy regarding fair value. Under this policy, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below. The adoption of this policy had no impact on our financial statements other than the disclosures presented herein.


Level 1		Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.

Level 2		Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Includes US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the valuation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE I – FAIR VALUE – (cont’d)


Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently only includes auction rate securities where independent pricing information was not able to be obtained. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities.

There were no changes in the level 3 fair value instruments for the six months ended November 30, 2010. There were no significant transfers in and out of Level 1 and 2 measurements for the six months ended November 30, 2010.


	Fair Value Measurements using inputs considered as:						Fair Value at Nov 30, 2010
	Level 1		Level 2		Level 3		Fair Value at Nov 30, 2010
Financial Assets
Cash equivalents
Money market funds	$	5,326	$	—	$	—	$	5,326
Corporate bond securities		—		6,498		—		6,498
U.S. government agency obligations		—		—		—		—

Total	$	5,326	$	6,498	$	—	$	11,824
Marketable securities
Corporate bond securities	$	—	$	31,740	$	—		31,740
U.S. government agency obligations		—		49,881		1,850		51,731

Total		—		81,621		1,850		83,471

Total Financial Assets	$	5,326	$	88,119	$	1,850	$	95,295


Financial Liabilities
Interest rate swap agreements	$	—	$	1,139	$	—	$	1,139

Total Financial Liabilities	$	—	$	1,139	$	—	$	1,139

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE I – FAIR VALUE – (cont’d)


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2010
	Level 1		Level 2		Level 3		Fair Value at May 31, 2010
Financial Assets
Cash equivalents
Money market funds	$	9,315	$	—	$	—	$	9,315
Corporate bond securities		—		17,996		—		17,996
U.S. government agency obligations		—		18,998		—		18,998

Total	$	9,315	$	36,994	$	—	$	46,309
Marketable securities
Corporate bond securities	$	—	$	24,172	$	—		24,172
U.S. government agency obligations		—		15,289		1,850		17,139

Total		—		39,461		1,850		41,311

Total Financial Assets	$	9,315	$	76,455	$	1,850	$	87,620

Financial Liabilities
Interest rate swap agreements	$	—	$	995	$	—	$	995

Total Financial Liabilities	$	—	$	995	$	—	$	995

In January 2010, the FASB updated the disclosure requirements for fair value measurements. The updated guidance requires companies to disclose separately the investments that transfer in and out of Levels 1 and 2 and the reasons for those transfers. Additionally, in the reconciliation for fair value measurements using significant unobservable inputs (Level 3), companies should present separately information about purchases, sales, issuances and settlements. The updated guidance is effective for the reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances and settlements in the Level 3 reconciliation, which are effective for fiscal years beginning after December 15, 2010. We have provided the additional disclosures necessary beginning with the first quarter of fiscal 2011.

We are exposed to market risk due to changes in interest rates. To reduce that risk, we periodically enter into certain derivative financial instruments to hedge its underlying economic exposure. We use derivative instruments as part of our interest rate risk management strategy. The derivative instruments used are floating-to-fixed rate interest rate swaps, which are subject to cash flow hedge accounting treatment. We recognized interest income of $45,000 and interest expense of $146,000 for the three months and six months ended November 30, 2010, respectively, and interest expense of $101,000 and $103,000 for the three and six months ended November 30, 2009, respectively.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE J – MARKETABLE SECURITIES

Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and reported at fair value, with unrealized gains and losses excluded from operations and reported as a component of accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality instruments, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate its position in the securities in the near term. At November 30, 2010 and May 31, 2010, we had $1.85 million in investments in two auction rate securities issued by New York state and local government authorities that had failed auctions. The authorities are current in their interest payments on the securities.

Marketable securities as of November 30, 2010 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	51,915	$	7	$	(191	)	$	51,731
Corporate bond securites		31,775		19		(54	)		31,740

	$	83,690	$	26	$	(245	)	$	83,471

Marketable securities as of May 31, 2010 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	17,174	$	14	$	(49	)	$	17,139
Corporate bond securites		24,179		46		(53	)		24,172

	$	41,353	$	60	$	(102	)	$	41,311

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE K – LITIGATION

AngioDynamics v. Vascular Solutions

On July 29, 2009, we filed a complaint in the United States District Court for the District of Delaware against Vascular Solutions, Inc. (NASDAQ: VASC). The complaint alleged that Vascular Solutions’ Vari-Lase Bright-Tip fiber product line infringed on claims of two of our patents, US 7,273,478 and US 7,559,329 (“the ‘478 and ‘329 patents”). These patents relate to methods of treating varicose veins using endovenous laser treatments. Vascular Solutions filed with the U.S. Patent & Trademark Office, or PTO, requests for inter partes reexamination of the ‘478 and ‘329 patents. The PTO initiated reexamination of these patents. No final ruling on the merits has been made at this time. Vascular Solutions denied the allegations of infringement and counterclaimed for a declaratory judgment that it does not infringe, that the patents are invalid and that the patents are unenforceable as a result of alleged inequitable conduct. Vascular Solutions did not seek damages but did seek attorney’s fees and costs of an unspecified amount should it prevail on its counterclaims and defenses. The case was transferred to the United States District Court for the District of Minnesota. On December 21, 2010 the parties entered into a confidential settlement agreement and filed with the Court a stipulation for entry of consent judgment pursuant to which Vascular Solutions has agreed that the asserted claims of the ‘478 and ‘329 patents are valid and enforceable. We granted Vascular Solutions a non-exclusive license under the ‘478 and ‘329 patents for an undisclosed amount. The parties filed in the PTO a stipulated motion to terminate the inter partes reexamination proceedings.

AngioDynamics v. biolitec

On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc., in which we are seeking judgment against biolitec for defense and indemnification costs we incurred in two lawsuits that have been settled by us. Biolitec has filed counter-claims against us seeking reimbursement of approximately $1.6 million in alleged past defense costs paid by biolitec in one of the settled cases.

On October 26, 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG, et al. In this action, we are asserting claims of tortious interference with contract, piercing the corporate veil, declaratory judgment, fraudulent transfer, and unfair or deceptive business practices against biolitec, Inc., biolitec AG (the corporate parent of biolitec, Inc.), a shareholder of biolitec AG and an executive of biolitec AG. The defendants have not yet answered, and no counterclaims have been asserted against us to date.

We will continue to vigorously enforce our rights under the supply agreement with biolitec. However, in the event it is ultimately determined that the claims asserted in the two settled cases are not within biolitec’s indemnification obligations under the biolitec supply agreement, we may be required to reimburse biolitec for the costs and expenses of defending the one settled case.

We are party to other legal actions that arise in the ordinary course of business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows.

AngioDynamics, Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

November 30, 2010 and November 30, 2009

(unaudited)

NOTE L – RECENTLY ADOPTED ACCOUNTING POLICIES

In October 2009, the FASB updated the revenue recognition accounting guidance relating to the accounting treatment for revenue arrangements that involve more than one deliverable or unit of accounting. The updated guidance allows companies to allocate arrangement considerations in multiple deliverable arrangements in a manner that better reflects the economics of the transaction by revising certain thresholds for separation, and providing criteria for allocation of revenue among deliverables. The updated guidance is effective for arrangements entered into in fiscal years beginning on or after June 15, 2010 (our 2012 fiscal year), but may be adopted early. We chose early adoption effective with the third quarter of fiscal 2010. The adoption had no material effect on our consolidated financial statements.

In October 2009, the FASB updated the accounting guidance relating to certain revenue arrangements that include software elements. The updated guidance clarifies the accounting for products that include both tangible product and software elements. This amendment is effective for fiscal years beginning after June 15, 2010 (our 2012 fiscal year), but companies are required to adopt these amendments in the same period as the amendments relating to revenue arrangements that involve more than one deliverable or unit of accounting. Therefore, we adopted the amendment effective with the third quarter of fiscal 2010. The adoption had no material effect on our consolidated financial statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2010.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

Overview

We are a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD, and local oncology therapy options for treating cancer, including radiofrequency ablation (“RF” or “RFA”) systems and embolization products for treating benign and malignant tumors. In addition, we provide our NanoKnife system for the ablation of soft tissue. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, interventional and surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases.

Previously we organized our business into three reportable segments: Peripheral Vascular, Access and Oncology. Effective June 1, 2010, we combined our Peripheral Vascular and Access reportable segments into a single reportable segment that was named the Vascular division and placed under the leadership of a general manager. At the same time we combined what had been separate Peripheral Vascular and Access sales groups into the Vascular sales group under the leadership of a vice president of sales reporting to the general manager. The Vascular segment is responsible for products targeting the venous intervention, venous access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology segment continues to be responsible for RF Ablation, embolization, Habib and NanoKnife product lines and has dedicated research and development and sales and marketing personnel assigned to it. For the past five fiscal years, approximately 95% of our net sales were from single-use, disposable products.

We sell our broad line of quality devices in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. For the three months ended November 30, 2010 and November 30, 2009 approximately 12% of our net sales were from markets outside the United States as compared with the six months ended November 30, 2010 and November 30, 2009, when approximately 11% of our net sales were from markets outside the United States.

Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in, research and development. For the three and six months ended November 30, 2010, our research and development (“R&D”) expenditures were $5.3 million and $10.5 million, respectively, which represented 9.9% and 10.0 % of net sales. This is compared to $4.8 million and $9.6 million in the prior year periods which constituted 8.9% and 9.3%, respectively, of net sales. R&D activities include research, product development, clinical studies, intellectual property affairs and regulatory affairs. We expect that our R&D expenditures will be between 8% and 10% of net sales in fiscal 2011 primarily due to investment in our NanoKnife technology. However, downturns in our business could cause us to reduce our R&D spending.

Except to the extent we can further use our cash and short term investments or our equity securities as acquisition capital, we will require additional equity or debt financing to fund any future significant acquisitions.

In recent years, we expanded our manufacturing and warehousing facilities in Queensbury, New York, to provide us with significantly greater manufacturing and warehousing capacity and to accommodate additional research, development and administrative requirements. We are not currently operating our manufacturing facilities at full capacity. In July 2009, we entered into an agreement to lease, for a ten year period plus 2 five year renewal options, a 52,500 square foot office building in Latham, New York. We commenced occupancy of the facility in Latham in March 2010.

Our ability to further increase our profitability will depend in part on improving gross profit margins. Factors such as changes in our product mix, new technologies and unforeseen price pressures may cause our margins to grow at a slower rate than we have anticipated, or to decline.

Recent Developments

Company reorganization

Previously we organized our business into three reportable segments: Peripheral Vascular, Access and Oncology. Effective June 1, 2010, we combined our Peripheral Vascular and Access reportable segments into a single reportable segment that was named the Vascular division and placed under the leadership of a general manager. At the same time we combined what had been separate Peripheral Vascular and Access sales groups into the Vascular sales group under the leadership of a vice president of sales reporting to the general manager. The Vascular segment is responsible for products targeting the venous intervention, venous access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology segment continues to be responsible for RF Ablation, embolization, Habib and NanoKnife product lines and has dedicated research and development and sales and marketing personnel assigned to it.

Results of Operations

Three Months ended November 30, 2010 and November 30, 2009

For the second quarter of fiscal 2011, we reported net income of $3.3 million, or $0.13 per diluted common share, on net sales of $53.4 million, compared with net income of $3.1 million, or $0.13 per diluted common share, on net sales of $53.5 million in the second quarter of the prior year. Gross profit was 59.1% in the second quarter of fiscal 2011, consistent with the 59.1% in the second quarter of the prior year.

The following table sets forth certain operating data as a percentage of net sales:


	Three Months Ended
	Nov 30, 2010			Nov 30, 2009
Net sales		100.0	%		100.0	%
Gross profit		59.1	%		59.1	%
Research and development expenses		9.9	%		8.9	%
Sales and marketing expenses		25.8	%		28.1	%
General and administrative expenses		9.3	%		7.5	%
Amortization of intangibles		4.0	%		4.6	%
Operating income		10.1	%		10.0	%
Other income (expenses)		(0.5	%)		(0.5	%)
Net income		6.1	%		5.9	%

Net sales. Net sales are derived from the sale of our products and related freight charges, less discounts and returns. Net sales of $53.4 million declined $87 thousand on an as reported basis and increased $63 thousand on a constant currency basis from the $53.5 million reported in the second quarter of 2010. This change in net sales was primarily attributable to a 2% decrease in average selling prices and decreased unit sales of dialysis products, Angiographic products, Sotradecol, Benephit renal infusion products and Habib resection devices, offset by increased unit sales of LC Beads, RF electrodes, vascular access ports and Nanoknife products.

From a reportable segment perspective, Vascular sales decreased 6% to $37.5 million from $39.8 million. This decrease was driven primarily by 4% lower average selling prices of Vascular products sold in the quarter and decreased unit sales of dialysis products, Angiographic products, Sotradecol and Benephit renal infusion products, partially offset by increased unit sales of vascular access ports, Venacure EVLT procedure kits, and micro access sets. Oncology sales were $15.9 million, an increase of 16% over prior year sales of $13.6 million primarily as a result of increased unit sales of LC Beads and Nanoknife generators and probes and a 3% increase in average selling prices, partially offset by decreased unit sales of Habib resection devices. Nanoknife sales totaled $1.6 million in the second quarter of fiscal 2011.

From a geographical perspective, U.S. sales decreased $785 thousand or 2% in the second quarter of fiscal 2011 to $46.7 million from $47.5 million a year ago. This decrease is primarily attributable to a 2% decrease in average selling prices and decreased unit sales of dialysis products, Angiographic products, Sotradecol, Benephit renal infusion products, RF electrodes and Habib resection devices. This decline was partially offset by increased unit sales of LC Beads, RF electrodes and Nanoknife products. International sales were $6.7 million in the fiscal second quarter of 2011, an increase of 12% from $6.0 million in the same period of fiscal 2010. Increased unit sales of Nanoknife products, RF Ablation products and vascular access ports comprised the majority of this increase. A decline in unit sales of VenaCure EVLT products partially offset these increases.

Gross profit. Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales was 59.1% in the second quarter of 2011, consistent with the prior year period. While there was no overall change in gross profit percentage in the comparable periods, continued pressure from the competitive pricing environment in the Vascular division resulted in 4% lower average selling prices on Vascular products from the prior year period which were offset by various programs to reduce material costs and improve factory utilization. Within the Oncology division increased gross profit resulted from increased unit sales of Nanoknife and LC Bead products and a 3% increase in average selling price of Oncology products. Overall, average selling prices declined by 2% in the second quarter compared to the same prior year period.

Research and development expenses. Research and development (“R&D”) expenses include costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical affairs and register and maintain our intellectual property. R&D expenses increased by $496 thousand, or 10%, to $5.3 million in the second quarter of fiscal 2011 compared to the same prior year period. The increase is primarily due to clinical and regulatory expenses related to our Oncology products and the cost of increased engineering headcount. As a percentage of net sales, R&D expenses were 9.9% for the fiscal second quarter of 2011, compared with 8.9% for the same period a year ago.

Sales and marketing expenses. Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and samples. S&M expenses decreased $1.2 million or 8% to $13.8 million in the second quarter of fiscal 2011 compared to the same prior year period. This decrease is primarily due to reduced commissions expense, reduced spending on marketing and promotion programs and a continued focus on managing discretionary spending. As a percentage of net sales, S&M expenses were 25.8% for the fiscal second quarter of 2011, compared with 28.1% for the prior year period.

General and administrative expenses. General and administrative (“G&A”) expenses include executive management, finance, accounting, legal, human resources and information technology and the administrative and professional costs associated with those activities. G&A expenses increased $914 thousand, or 23%, to $4.9 million in the second quarter of fiscal 2011 compared to the same prior year period primarily due to $772 thousand in severance and restructuring costs. Other factors include increased costs related to the Latham, NY facility, expansion of our business development function and to personnel and other infrastructure costs to support our growth. G&A expenses increased to 9.3% of net sales compared with 7.5% in the prior year period.

Amortization of intangibles. Amortization of intangibles was $2.1 million in the second quarter of fiscal 2011 compared with $2.5 million in the second quarter of fiscal 2010.

Operating income. Operating income was $5.4 million and $5.3 million for the second quarter of fiscal 2011 and 2010, respectively. As a percentage of sales, operating income remained at 10.1% for the second quarter of 2011 compared with 10.0% in the same prior year period.

Other income (expenses). Other income and expenses for the second quarter of fiscal 2011 was $262 thousand of net expense compared with $290 thousand of net expense in the same period a year ago, both representing 0.5% of net sales in their respective periods.

Income taxes. Our effective tax rate was 36% for the fiscal second quarter of 2011 compared with 38% for the same prior year period. The current quarter reflects an increased benefit from the Domestic Production Activities Deduction, partially offset by the December 31, 2009 expiration of the R&D tax credit.

Net income. For the second quarter of 2011, we reported net income of $3.3 million, an increase of $150 thousand from net income of $3.1 million for the prior year quarter.

Investment in Nanoknife Technology. The sales and costs associated with the Nanoknife technology is recorded in our Oncology division. Taking into account the sales and the related cost of sales and operating expenses, the net impact of our investment in Nanoknife technology in the second fiscal quarter of 2011 was $1.5 million on pretax income and $1.0 million or ($0.04) per share after tax compared with $2.2 million on pretax income and $1.4 million or ($0.06) per share after tax in the second fiscal quarter of 2010.

Six Months ended November 30, 2010 and November 30, 2009

For the first six months of fiscal 2011, we reported net income of $5.2 million, or $0.21 per diluted common share, on net sales of $104.9 million, compared with net income of $5.2 million, or $0.21 per diluted common share, on net sales of $103.6 million in the first six months of the prior year. Gross profit was 58.7% in the first six months of fiscal 2011 compared with 59.6% in the first six months of the prior year.

The following table sets forth certain operating data as a percentage of net sales:


	Six Months Ended
	Nov 30, 2010			Nov 30, 2009
Net sales		100.0	%		100.0	%
Gross profit		58.7	%		59.6	%
Research and development expenses		10.0	%		9.3	%
Sales and marketing expenses		26.9	%		29.4	%
General and administrative expenses		9.1	%		7.8	%
Amortization of intangibles		4.2	%		4.6	%
Operating income		8.5	%		8.6	%
Other income (expenses)		(0.8	%)		(0.4	%)
Net income		4.9	%		5.1	%

Net sales. Net sales for first six months of fiscal 2011 increased by 1%, or $1.3 million on an as reported basis and 2% or $1.6 million on a constant currency basis, to $104.9 million from $103.6 million in the first six months of the prior year. The growth in net sales was primarily attributable to increased unit sales of LC Beads, Nanoknife products, and micro access sets offset by a 2% overall decrease in average selling prices and decreased unit sales of dialysis products, Habib resection devices, Angiographic and PTA (percutaneous transluminal angioplasty) catheters, and Benephit renal infusion products.

From a reportable segment perspective, Vascular sales decreased 5% to $73.4 million from $77.1 million. This decrease is primarily attributable to 4% lower average selling prices of Vascular products and decreased unit sales of dialysis products, Angiographic and PTA catheters, and Benephit renal infusion products, partially offset by increased unit sales of vascular access ports, Venacure EVLT procedure kits, and micro access sets. Oncology sales were $31.4 million, an increase of 19% over the prior year primarily as a result of increased unit sales of our LC Beads and Nanoknife products and a 3% increase in average selling prices, partially offset by decreased unit sales of Habib resection devices. Nanoknife sales totaled $2.7 million in the first six months of fiscal 2011.

From a geographical perspective, U.S. sales decreased $225 thousand or 0.2% in the first six months of fiscal 2011 to $92.2 million from $92.4 million a year ago. This decrease is primarily attributable to a 2% overall decrease in average selling prices and decreased unit sales of dialysis products, Habib resection devices, Angiographic and PTA catheters, and Benephit renal infusion products partially offset by increased unit sales of LC Beads, Nanoknife products, and micro access sets. International sales were $12.7 million in the six month period ended November 30, 2010, an increase of 14% and 17% on a constant currency basis from $11.2 million in the same period of fiscal 2010. Increased unit sales of RF Ablation products, Nanoknife products and vascular access ports comprised the majority of this increase which was partially offset by a decline in unit sales of VenaCure EVLT products.

Gross profit. Our gross profit as a percentage of sales was 58.7% in the first six months of fiscal 2011 compared with 59.6% for the same period in the prior year. In addition to the volume changes described above, the decrease in gross profit percentage was also attributable to 4% lower average selling prices for Vascular products, partially offset by 3% higher average selling prices for Oncology products.

Research and development expenses. R&D expenses increased by $889 thousand, or 9%, to $10.5 million in the six month period ended November 30, 2010 compared to the same period in the prior year. The increase is primarily due to increased engineering headcount and to increased costs necessary to fund clinical research projects for our Oncology products. As a percentage of net sales, R&D expenses were 10.0% for the six month period ended November 30, 2010, compared with 9.3% for the same prior year period.

Sales and marketing expenses. S&M expenses decreased $2.2 million or 7% to $28.2 million in the first six months of fiscal 2011 compared to the same period in the prior year. This decrease is primarily due to reduced spending in marketing and promotion programs, reduced commissions expense and a continued focus on managing discretionary spending. As a percentage of net sales, S&M expenses were 26.9% for the first six months of fiscal 2011, compared with 29.4% for the prior year period.

General and administrative expenses. G&A expenses increased $1.4 million, or 18%, to $9.5 million in the first six months of fiscal 2011 compared to the same period in the prior year due to $772 thousand in severance and restructuring costs, increased costs associated with the Latham, NY facility, expansion of our business development function and to personnel and other infrastructure costs to support our growth. G&A expenses increased to 9.1% of net sales compared with 7.8% in the prior year period.

Amortization of intangibles. Amortization of intangibles was $4.4 million in the six month period ending November 30, 2010 compared to $4.7 million in the prior year period.

Operating income. Operating income was $8.9 million for the both the first six months of fiscal 2011 and 2010. As a percentage of sales, operating income for the first six months of 2011 declined to 8.5% compared with 8.6% in the prior year same period.

Other income (expenses). Other income and expenses for the first six months of fiscal 2011 was $790 thousand of net expense, or (0.8%) of net sales compared with $455 thousand of net expense, representing (0.4%) of net sales in the same period a year ago. The increase in expense is primarily related to increased foreign exchange losses, increased other investment losses and increased credit card fees partially offset by reduced expense from an interest rate swap.

Income taxes. Our effective tax rate was 36% for the six month period ending November 30, 2010 compared with 38% for the same prior year period. The current year to date period reflects an increased benefit from the Domestic Production Activities Deduction, partially offset by the December 31, 2009 expiration of the R&D tax credit.

Net income. For the first six months of fiscal 2011, we reported net income of $5.2 million, consistent with the same prior year period.

Investment in Nanoknife Technology. Taking into account the sales and related cost of sales and operating expenses, the net impact of our investment in Nanoknife technology in the first half of 2011 was $3.1 million on pretax income and $2.0 million or ($0.08) per share after tax compared with $4.7 million on pretax income and $2.9 million or ($0.12) per share after tax in the first half of 2010.

Liquidity and Capital Resources

Our cash, cash equivalents and marketable securities totaled $110.6 million at November 30, 2010, compared with $100.1 million at May 31, 2010. Marketable securities consisted of U.S. government issued or guaranteed securities, corporate bonds and auction rate securities. At November 30, 2010, total debt was $6.7 million comprised of short and long-term bank debt that financed our facility expansions in Queensbury, New York. This compared with $6.8 million at May 31, 2010.

Summary of cash flows (in thousands):


	Six Months ended
	Nov 30, 2010			Nov 30, 2009
Cash provided by (used in):
Operating activities	$	11,626		$	12,381
Investing activities		(43,883	)		(4,870	)
Financing activities		588			826
Effect of exchange rate changes on cash and cash equivalents		38			10

Net change in cash and cash equivalents	$	(31,631	)	$	8,347

Net cash provided by operating activities for the six months ended November 30, 2010 was $11.6 million compared with $12.4 million in the same prior year period. Cash generated from operating activities during the first six months of fiscal year 2011 was primarily the result of net income and the effect on net income of non cash items, such as depreciation and amortization and stock-based compensation, as well as a decrease in accounts receivable and prepaid expenses and other assets offset by decreases in accounts payable and accrued liabilities and increases in inventories. The prior year period consisted of similar components.

Net cash used in investing activities was $43.9 million for the six months ended November 30, 2010 compared with $4.9 million for the same prior year period. The net cash provided by investing activities in the first six months of 2011 and 2010 consisted primarily of net purchases of marketable securities and available-for-sale short term investments.

Net cash provided by financing activities was $588 thousand for the six months ended November 30, 2010 compared to $826 thousand for the comparable prior year period. Cash provided by financing activities for the both periods primarily consisted of proceeds from purchases under the employee stock purchase plan and proceeds from the exercise of stock options.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2010.

In July 2009, we entered into an agreement to lease, for a ten year period plus 2 five year renewal options, a 52,500 square foot office building in Latham, New York that houses our corporate headquarters and certain business operations. We commenced occupancy of the facility in March 2010. The agreement provides for annual rent of $857,321 for the first five years and $943,054 for the next five years, plus the payment of customary building operating expenses. The lease commencement date was March 1, 2010.

We believe that our current cash and investment balances, together with cash generated from operations, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant additional acquisitions of other businesses or technologies for cash, we may require external financing. We cannot assure you that such financing will be available on commercially reasonable terms, if at all.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk due to changes in interest rates. To reduce that risk, we periodically enter into certain derivative financial instruments to hedge our underlying economic exposure. We use derivative instruments as part of our interest rate risk management strategy. The derivative instruments used are floating-to-fixed rate interest rate swaps, which are subject to cash flow hedge accounting treatment.

At November 30, 2010, we maintained variable interest rate financing of $6.7 million in connection with our facility expansions. We have limited our exposure to interest rate risk by entering into interest rate swap agreements with a bank under which we agreed to pay the bank fixed annual interest rate of 4.45% and 5.06% and the bank assumed our variable interest payment obligations under the financing.

Nearly all of our sales have historically been denominated in United States dollars. In fiscal 2007 we began to make sales in other currencies, particularly the Euro, GB pound and Canadian dollar. Approximately 4% of our sales in the first six months of fiscal 2011 were denominated in currencies other than the US dollar, primarily the Euro and GB pound. We currently have no significant direct foreign currency exchange risk.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investments. ARS typically are high credit quality instruments, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have $1.85 million in investments in two auction rate securities issued by New York state and local government authorities that have failed auctions. The authorities are current in their interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business as described in Note K.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiaries) in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting in the fiscal quarter ended November 30, 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

AngioDynamics, Inc. and Subsidiaries

Part II: Other Information

Item 1.

Legal Proceedings.

Certain legal proceedings in which we are involved are described in our annual report on Form 10-K for the fiscal year ended May 31, 2010. There have been no material developments in such proceedings during the period covered by this quarterly report on Form 10-Q, other than the settlement reached on December 21, 2010 in the AngioDynamics v. Vascular Solutions proceedings discussed in Note K herein.

We are party to legal actions that arise in the ordinary course of business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Item 1A.

Risk Factors.

In addition the risk factor set forth below and the other information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2010 which sets forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk.

Supply and Distribution Agreement with Biocompatibles UK Limited

We sell the embolization product, LC Bead, pursuant to a Supply and Distribution Agreement with Biocompatibles UK Limited that grants us the exclusive distribution rights to the product in the United States. The Agreement was entered into in April 2006 and was amended in October 2007, June 2008, March 2009 and March 2010. Under the Agreement, we are required to purchase certain minimum levels of product from Biocompatibles. The March 2010 Amendment specifies distribution rights until December 31, 2011. During the second fiscal quarter of 2011, LC Beads accounted for approximately 12% of our net sales and 13% of net sales in the first half of the fiscal year. On November 19, 2010, the boards of BTG PLC and Biocompatibles announced they have reached agreement with terms of a proposal whereby BTG will acquire the entire share capital of Biocompatibles. Failure to extend our distribution rights to LC Bead after December 31, 2011, could have an adverse effect on our operations.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

(Removed and Reserved)

Item 5.

Other Information.

None.

Item 6.

Exhibits.


No.		Description

31.1		Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.

31.2		Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


				ANGIODYNAMICS, INC.
				(Registrant)

Date: January 7, 2011				/s/ JOHANNES C. KELTJENS
				Johannes C. Keltjens, President,
				Chief Executive Officer
				(Principal Executive Officer)

Date: January 7, 2011				/s/ D. JOSEPH GERSUK
				D. Joseph Gersuk, Executive Vice President,
				Chief Financial Officer
				(Principal Financial and Chief Accounting Officer)

EXHIBIT INDEX


No.		Description

31.1		Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.

31.2		Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company